CPU0213, a novel endothelin receptor antagonist, suppresses the upregulation of matrix metalloproteinases and connexin 43 in hyperthyroid myocardium.
It has been verified that endothelin-1 (ET-1) activates matrix metalloproteinase (MMP) in the process of myocardial remodeling. Sustained high thyroid hormone level gives rise to left ventricular hypertrophy, in which the ET-1 system is probably involved.We attempted to study the effects of CPU0213, a novel endothelin receptor antagonist, on myocardial remodeling induced by high dose L-thyroxin. Adult male Sprague-Dawley rats were treated with L-thyroxin (0.4 mg/kg/d, sc) for 10 days to induce left ventricular hypertrophy. Asubset of rats was given CPU0213 from day 6 to 10. Alterations in MMP, tissue inhibitor of metalloproteinase (TIMP), and connexin 43 were measured by reverse transcription polymerase chain reaction (RT-PCR), zymography, and Western blot assays. L-thyroxin treatment resulted in increased mRNA expression and MMP-2 and MMP-9 activities, along with decreased TIMP-1 and TIMP-2 mRNA expression. CPU0213 suppressed the increased activity of MMP, and prevented the downregulation of TIMP expression. The expression of connexin 43 was upregulated at both mRNAand protein levels after L-thyroxin treatment, which was attenuated by CPU0213. In addition, L-thyroxin caused upregulation of mRNA expression of preproET-1 (ppET-1) and endothelin converting enzyme (ECE). These results suggest that the ET receptors mediate high dose L-thyroxin induced myocardial remodeling by changing MMP, TIMP activities and connexin 43.
Tang
Xiao-Yun
XY
Research Division of Pharmacology, China Pharmaceutical University, Nanjing 210009, China.
Liu
Qing
Q
Dai
De-Zai
DZ
Dai
Yin
Y
D000818:Animals; D009202:Cardiomyopathies / Q000201:enzymology* / Q000209:etiology; D018031:Connexin 43 / Q000187:drug effects* / Q000378:metabolism; D065128:Endothelin Receptor Antagonists; D006980:Hyperthyroidism / Q000139:chemically induced / Q000150:complications* / Q000201:enzymology; D008297:Male; D020782:Matrix Metalloproteinases / Q000187:drug effects* / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013974:Thyroxine / Q000009:adverse effects; D015854:Up-Regulation / Q000187:drug effects
C513821:CPU0213; D018031:Connexin 43; D065128:Endothelin Receptor Antagonists; D011720:Pyrazoles; D020782:Matrix Metalloproteinases; D013974:Thyroxine